Takeda (TAK) announced that the European Commission approved Adcetris in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use on April 25, the company noted.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Positive Outlook for Takeda Pharmaceutical Co: Buy Rating Supported by Promising Phase 3 Data and Projected Sales for Rusfertide
- Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
- Veeva price target raised to $300 from $270 at Needham
- Takeda Reports Changes in Subsidiaries and Associates as of May 28, 2025
- Takeda Announces CEO Succession and Advocates for Healthcare Reforms
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue